Competitive repopulation assays demonstrate the in vivo selective growth advantage of HOXB4-transduced CD34+ cells
| Experiment and group . | No. mice . | Ratio of GFP+to RFP+ in input cells . | Analysis of engraftment . | |||
|---|---|---|---|---|---|---|
| A, GFP+ as % of CD34+ . | B, RFP+ as % of CD34+ . | Ratio of A to B . | % CD45* . | |||
| No. 1 | ||||||
| HOX/RFP | 6 | 0.5 | 45.8 ± 10.7† | 7.6 ± 2.1 | 8.6 ± 4.0† | 12.5 ± 4.1 |
| GFP/RFP | 6 | 1.0 | 22.8 ± 4.2 | 35.5 ± 10.0 | 1.2 ± 0.6 | 10.0 ± 3.7 |
| No. 2 | ||||||
| HOX/RFP | 7 | 1.0 | 29.2 ± 9.6† | 4.8 ± 2.7 | 49.0 ± 40.0 | 24.6 ± 6.7 |
| GFP/RFP | 6 | 1.4 | 18.5 ± 10.6‡ | 4.8 ± 3.8 | 13.7 ± 14.7‡ | 11.7 ± 4.5 |
| Experiment and group . | No. mice . | Ratio of GFP+to RFP+ in input cells . | Analysis of engraftment . | |||
|---|---|---|---|---|---|---|
| A, GFP+ as % of CD34+ . | B, RFP+ as % of CD34+ . | Ratio of A to B . | % CD45* . | |||
| No. 1 | ||||||
| HOX/RFP | 6 | 0.5 | 45.8 ± 10.7† | 7.6 ± 2.1 | 8.6 ± 4.0† | 12.5 ± 4.1 |
| GFP/RFP | 6 | 1.0 | 22.8 ± 4.2 | 35.5 ± 10.0 | 1.2 ± 0.6 | 10.0 ± 3.7 |
| No. 2 | ||||||
| HOX/RFP | 7 | 1.0 | 29.2 ± 9.6† | 4.8 ± 2.7 | 49.0 ± 40.0 | 24.6 ± 6.7 |
| GFP/RFP | 6 | 1.4 | 18.5 ± 10.6‡ | 4.8 ± 3.8 | 13.7 ± 14.7‡ | 11.7 ± 4.5 |
At 24 hours after the last infection, CD34+ cells transduced either with HOXB4 or GFP control virus were each mixed with equal numbers of RFP-transduced CD34+ cells, and then injected into NOD/SCID mice. Mice were killed 8 weeks later, and their bone marrow was analyzed for human cells expressing GFP or RFP. Results are shown as the mean ± SE.
Proportion of all viable (PI−) cells in retrieved bone marrow of the chimeric mice.
Student t test (paired; 2-sided). P < .05.
Values for GFP+ cells normalized to input ratio of 1:1.